

## **ASX RELEASE**

11 January 2021

#### **CLOSING DATE EXTENDED FOR RIGHTS ISSUE**

# Closing date extended to 3 February 2021 for

## non-renounceable entitlement offer

Beston Global Food Company Limited (ASX: BFC, "Beston") advises that the closing date for the non-renounceable entitlement offer, raising up to \$15.6 million ("Entitlement Offer"), has been extended to Wednesday 3 February 2021.

The extension of the closing date is as a result of requests from shareholders and the Company becoming aware that many shareholders who receive their correspondence by mail have still not received their Offer Documents as of 8 January, 2021. The delay in the delivery of mailed documents appears to be a result of operating constraints in the postal service over the Christmas and New Year holiday period.

The Board of Beston has resolved to extend the Offer period until 5:00pm ACDT on Wednesday 3 February 2021 in order to ensure that eligible shareholders have an appropriate amount of time to consider the Offer Documents and to make an informed decision on the Entitlement Offer.

The possible extension of the closing date was highlighted in recent communications for the Entitlement Offer as an option should the Board of Beston deem it to be necessary.

The purpose of the Offer is to provide the "top up" funds of \$7.25 million as required under the conditions of the SA Government \$2.0 million grant for the accelerated expansion (Stage 2) of the Company's Lactoferrin plant at Jervois SA, and to

undertake various plant upgrades at the Jervois factory to ensure that the plant is able to operate reliably on a 24 hour/7 days a week basis with higher planned milk intake. The time extension will not affect the timing of the work on the Stage 2 expansion of the Lactoferrin plant.

## **Use of Funds**

The table below provides further detail on the use of funds from the Entitlement Offer related to the Stage 2 lactoferrin expansion and the Jervois upgrades.

	Cost	Capital Item	Comments	Est.
				completion <sup>1</sup>
Stage 2	(\$2.0m)	SA Government	Conditional on Beston	Feb-21
Lactoferrin		Regional Growth	funding the additional	
expansion		Grant	Stage 2 costs	
	\$1.5m	2 <sup>nd</sup> lactoferrin	Deliver additional FY22	Mar-21
		extraction column	production capacity of ~8	
			Tpa based on 160ML milk	
			supply	
	\$1.0m	Other	Critical spares and testing	Mar-21
			equipment	
	\$7.0m	Lactoferrin spray	Ability to broaden offering	Mar-22
		dryer and packing	of dried lactoferrin	
			product at a premium	
			price	
Jervois	\$2.1m	Milk Silo	Increase milk storage	Jul-21
Upgrades		expansion	capacity by 1ML	
	\$0.75m	2nd Multivac	Multivac increases	Sept-21
			handling rate for higher	
			mozzarella production	
	\$2.25m	2 <sup>nd</sup> Boiler	Boiler increases reliability	Dec-21
			for 24/7 operations	
	\$2.0m	Mozzarella	Automated end-of-line	Dec-21
		automated	packing and palletising of	
		packing	mozzarella	

Total	\$14.6m	Stage 2 lactoferrin	
capital		expansion: \$7.5m	
projects		Jervois upgrades: \$7.1m	
Costs <sup>2</sup> of	\$1.0m		
Offer			
Total	\$15.6m		
funds to			
be raised			

<sup>&</sup>lt;sup>1</sup> Expected project completion timing with best endeavours undertaken to meet completion dates. Significant expenditure in the way of initial deposits and progress payments will be incurred ahead of the expected completion dates. It is currently estimated that c. 65% of the funds raised will be expended by 30 June 21 and c. 90% by 30 September 21.

If less than the full \$15.6 million is raised under the Entitlement Offer, (noting that the underwritten portion of the Entitlement Offer (\$7.25 million) will cover the Stage 2 lactoferrin expansion) the remaining funds available will be applied against the Jervois upgrades in a manner determined by Beston to be the most value accretive

### **Indicative Timetable**

Key dates relating to the Entitlement Offer are identified in the table below. The Company, in consultation with the Joint Lead Managers, reserves the right to amend this timetable subject to the Corporations Act and the ASX Listing Rules.

Key dates		
Equity Raising announcement	Thursday, 17 December 2020	
Ex Date	Tuesday, 22 December 2020	
Record date for determining entitlement for the Entitlement Offer	Wednesday, 23 December 2020	
Dispatch of Offer Booklet and Entitlement Offer opens	Tuesday, 29 December 2020	
Entitlement Offer closing date	Wednesday, 3 February 2021	
Announcement of results of Issue	Monday, 8 February 2021	
Issue and Allotment of New Shares under the Entitlement Offer	Wednesday, 10 February 2021	
Normal trading of New Shares issued under the Entitlement Offer and dispatch of Holding statements	Thursday, 11 February 2021	

<sup>&</sup>lt;sup>2</sup> Assuming the full \$15.6 million is raised.

4.

Significance of Lactoferrin

Lactoferrin is an iron-binding glycoprotein which is known to be essential in boosting

the immune system in the human body. It has anti-bacterial, anti-viral, anti-

parasitic and anti-allergic functions and properties.

Importantly, particularly in the context of the current COVID-19 pandemic, it has

been shown to supress virus replication by affecting natural killer cells in the human

body which play a crucial role in the early stages of viral infections.

Clinical trials are underway around the world on the efficacy of using Lactoferrin as

a treatment for COVID-19. Although the number of trials are limited to date, the

early results indicate that Lactoferrin may inhibit coronavirus from replicating in the

human body.

The findings have further increased the global demand for Lactoferrin, particularly

in Europe and China, where it is known as "pink gold" because of its price (around

\$1,500 per kilogram) and reddish hue after processing. Market studies undertaken

before the advent of COVID-19 predicted that demand for Lactoferrin would

increase by around 60% over the next few years.

The plant expansion project being undertaken by Beston will increase Australia's

self-sufficiency in the production of immune boosting Lactoferrin and will enhance

the bio-security of the nation.

This ASX release was approved and authorised for release by Dr Roger Sexton AM,

Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

John Hicks Chief Executive Officer +61 8 8470 6500

jhicks@bestonglobalfoods.com.au

Darren Flew Chief Financial Officer +61 8 8470 6500

dflew@bestonglobalfoods.com.au

Social Media Handles:

Facebook: Twitter: Instagram:

@bestonglobalfoods @BestonGlobal @bestonglobal

@edwards.crossing @edwardscrossing

@mablesaustralia @mablesaustralia

#### ABOUT BESTON GLOBAL FOOD COMPANY LIMITED

Beston Global Food Company is a proud South Australian multi award-winning company taking the best of Australian produce to the world with fresh milk supplied by valued farmers. The company provides direct and indirect employment for nearly 300 people. For more information please visit: <a href="https://www.bestonglobalfoods.com.au">www.bestonglobalfoods.com.au</a>

#### NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be registered, under the US Securities Act of 1993, as amended (the "Securities Act") and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the Securities Act and applicable US state securities laws.